Endocrine and metabolic indices during progestin (quingestanol) therapy.
Quingestanol at 300 y/day was well tolerated during 1 to 12 months of therapy of pre-menopausal and menopausal women with minimal changes, if any, in  a battery of routine endocrine and metabolic indices. Serum inorganic phosphorus levels were slightly above the pre-therapy range but still within normal limits during the 12 months of treatment and the mean relative blood volume or hematocrit during the latter 6 months was slightly above the starting value.
D000328:Adult; D001609:Beta-Globulins / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis; D001810:Blood Volume / Q000187:drug effects; D004341:Drug Evaluation; D004967:Estrogens / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D009649:Norpregnadienes / Q000627:therapeutic use*; D010758:Phosphorus / Q000097:blood; D013256:Steroids / Q000652:urine; D013997:Time Factors
D001609:Beta-Globulins; D001786:Blood Glucose; D004967:Estrogens; D007328:Insulin; D009649:Norpregnadienes; D013256:Steroids; D010758:Phosphorus; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone